Droxicam
Based on 1 Customer Validation
Droxicam (Ombolan) is a non-steroidal anti-inflammatory agent, with strong analgesic activity. Droxicam acts by inhibiting PGE2 varies, and is characterised by being a pro-drug of Piroxicam (HY-B0253). Droxicam is well tolerated with slight side effects in the said mucosa. Droxicam does not show cardiovascular or respiratory effects in cats, and inhibits peritoneal capillary permeability in mouse.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.59%
- CAS No.: 90101-16-9
- Formule: C16H11N3O5S
- Masse moléculaire:357.34
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vivo
Droxicam (ED50, p.o.; 5, 6, 7, 8 h; 7.5, 12.9, 4.8, 8.4 mg/kg) shows high antiinflammatory activity against nystatin-induced edema in rat[1].
Droxicam (ED50, p.o., 1, 2, 3, 4 h: 0.51, 0.94, 1.56, 4.88 mg/kg) shows protective effects in U.V. light-induced erythema in guinea pigs[1].
Droxicam (0.1 mg/kg, 0.33 mg/kg, 1 mg/kg; po; once daliy) shows good antiarthritic activity in rats injected with Mycobacterium butyricum against primary and secondary lesions[1].
Droxicam demonstrates strong analgesic activity in protecting against writhings : induced by phenylbenzoquinone in mice, induced by acetylcholine bromide in mice, with ED50s of 5.3 mg/kg and 1.1 mg/kg, respectively[1].
Droxicam (ED50=0.081 mg/kg; po) protects rat against diarrhea induced by castor oil[1].
Droxicam significantly inhibits peritoneal capillary permeability in mice[1].
Droxicam does not alter rat behavior (80 mg/kg, i.p.) nor that of mice (160 mg/kg, p.o.) in the Irwin's test[1].
Droxicam does not exhibit uricosuric activity in rats, neither shows cardiovascular or respiratory effects in anesthetized cats, nor modify their response to administration of acetylcholine, norepinephrine and histamine[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 90101-16-9
-
Appearance Solid
-
Masse moléculaire 357.34
-
Formule C16H11N3O5S
-
Color White to off-white
-
SMILES
O=C(N1C2=CC=CC=N2)C(N3C)=C(OC1=O)C4=C(C=CC=C4)S3(=O)=O
-
Synonyms
Ombolan
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 50 mg/mL (139.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Transepithelial/transendothelial electrical resistance assay
TEER measures electrical resistance across epithelial or endothelial monolayers cultured on permeable supports, and the readout reflects ionic conductance through the cell barrier, especially the paracellular pathway regulated by junctional integrity. TEER can be measured without destroying the monolayer and is commonly used before or during transport, permeability, barrier-disruption, and barrier-maturation experiments. TEER values are influenced by biological maturation and technical conditions; reported factors include temperature, medium formulation, passage number, electrode geometry, membrane properties, and junctional length during early monolayer maturation. Therefore, TEER should be interpreted with blank-insert subtraction, area normalization, repeated readings, and, when possible, orthogonal barrier readouts such as FITC-dextran flux or tight-junction staining.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Farré AJ, et al. Pharmacological properties of droxicam, a new non-steroidal anti-inflammatory agent. Methods Find Exp Clin Pharmacol. 1986 Jul;8(7):407-22. [Content Brief]
[2]. Jané F, et al. Droxicam: a pharmacological and clinical review of a new NSAID. Eur J Rheumatol Inflamm. 1991;11(4):3-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7985 mL | 13.9923 mL | 27.9846 mL | 69.9614 mL |
| 5 mM | 0.5597 mL | 2.7985 mL | 5.5969 mL | 13.9923 mL | |
| 10 mM | 0.2798 mL | 1.3992 mL | 2.7985 mL | 6.9961 mL | |
| 15 mM | 0.1866 mL | 0.9328 mL | 1.8656 mL | 4.6641 mL | |
| 20 mM | 0.1399 mL | 0.6996 mL | 1.3992 mL | 3.4981 mL | |
| 25 mM | 0.1119 mL | 0.5597 mL | 1.1194 mL | 2.7985 mL | |
| 30 mM | 0.0933 mL | 0.4664 mL | 0.9328 mL | 2.3320 mL | |
| 40 mM | 0.0700 mL | 0.3498 mL | 0.6996 mL | 1.7490 mL | |
| 50 mM | 0.0560 mL | 0.2798 mL | 0.5597 mL | 1.3992 mL | |
| 60 mM | 0.0466 mL | 0.2332 mL | 0.4664 mL | 1.1660 mL | |
| 80 mM | 0.0350 mL | 0.1749 mL | 0.3498 mL | 0.8745 mL | |
| 100 mM | 0.0280 mL | 0.1399 mL | 0.2798 mL | 0.6996 mL |
Droxicam Related Classifications
HY-107345 Related Classifications
Powered by Bioz